Novo Nordisk has launched the first GLP-1 weight-loss pill in the United States.
The once-daily Wegovy pill is priced significantly below injectable weight-loss drugs.
It is the first and only pill on the market that mimics the GLP-1 hormone to reduce appetite.
Self-paying patients can access the starting dose for $149 a month.
Higher doses will rise to $199 and $299 later in the year.
Patients with insurance may pay as little as $25 a month.
The pill offers a needle-free alternative to injections like Wegovy and Ozempic.
Analysts say the pricing is lower than expected and pressures rivals.
Novo faces strong competition from Eli Lilly and its drugs Mounjaro and Zepbound.
Shares rose after the launch despite steep declines over the past year.
The pill is available through major US pharmacies and telehealth providers.
US approval comes as regulators in the UK continue reviewing the drug.
Novo Nordisk Launches Wegovy Weight-Loss Pill in US, Intensifying Price War
Andrew Rogers
Andrew Rogers is a freelance journalist based in the USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He earned his degree in Journalism from the University of Florida. Throughout his career, he has contributed to outlets such as The New York Times, CNN, and Reuters. Known for his clear reporting and in-depth analysis, Andrew delivers accurate and timely news that keeps readers informed on both national and international developments.
Add A Comment
NY Evening Post delivers powerful stories, breaking news, sports, and culture—bringing bold perspectives and timely updates to keep readers informed, inspired, and connected worldwide.
We’re social. Connect with us:
© 2026 NY Evening Posts. All Rights Reserved.